Study of BH4, a New and Simple Treatment of Mild PKU
The main purpose is to test whether treatment with BH4-tablets can replace the protein restrictive diet in patients with mild PKU caused by a certain frequent mutation.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Study of the Response of Tetrahydrobiopterin on S-Phenylalanine in Patients With PKU Housing the Y414C Mutation|
- Fasting S-phenylalanine at day 0, 1, 2, 5, 7 in each week of treatment with BH4.
|Study Start Date:||April 2005|
|Estimated Study Completion Date:||December 2005|
PKU, phenylketonuria, is a rare, inherited metabolic disorder that results in mental retardation if not a very strict low-protein diet is started within the first weeks of life.
The conversion of phenylalanine, phe, to tyrosine is defect, phe accumulates, leading to brain damage. There are different degrees of severity, reflecting the spectrum of mutant genes. BH4, tetrahydrobiopterin, is a co-enzym for the conversion of phe to tyrosine. It is known that BH4 can lower phe in some patients with milder forms of PKU.
The main purpose is to test whether treatment with oral BH4 can replace the protein restrictive diet in patients with mild PKU caused by the frequent mutation Y414C in the phenylalanine hydroxylase gene.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00260000
|The Kennedy Institute-National Eye Clinic|
|Glostrup, Copenhagen, Denmark, DK-2600|
|Principal Investigator:||Jytte B Nielsen, DMSc||The Kennedy Institute-National Eye Clinic|